What Does ‘Bioidentical’ Actually Mean?
The term “bioidentical” refers to hormones that are chemically identical in molecular structure to the hormones naturally produced by the human body. This includes estradiol (E2), estriol (E3), progesterone, testosterone, DHEA, and others. The key distinction from synthetic hormones is that bioidentical hormones fit hormone receptors with the same affinity as endogenous hormones — though the clinical significance of this distinction continues to be debated in the literature.
FDA-Approved Bioidentical Hormones
Contrary to common misconception, FDA-approved bioidentical hormone products exist and are widely used. These include estradiol patches (Vivelle-Dot, Climara), estradiol gels (Divigel, EstroGel), estradiol spray (Evamist), vaginal estradiol cream/ring/tablet, and micronized progesterone (Prometrium). These products are standardized, studied, and FDA-regulated — representing the evidence-based backbone of bioidentical HRT.
Compounded Bioidentical Hormones
Compounded BHRT (cBHRT) is prepared by licensed 503A compounding pharmacies and customized to individual patient prescriptions — allowing unique dose combinations, delivery methods, and formulations not available commercially. Tri-est (E1/E2/E3 combinations), custom-dose testosterone creams, and bi-est pellets are examples. While cBHRT fills important clinical gaps, it carries regulatory uncertainty, inconsistent potency, and limited safety data compared to FDA-approved products.
The Evidence on Safety: What We Know
Much of the safety concern around HRT originates from the Women’s Health Initiative (WHI) study, which used conjugated equine estrogens (Premarin) and medroxyprogesterone acetate — neither of which is bioidentical. More recent data, including the KEEPS and ELITE trials, suggests that bioidentical estradiol plus micronized progesterone carries a significantly more favorable cardiovascular and breast cancer risk profile — particularly when initiated in the “window of opportunity” (within 10 years of menopause or before age 60).
Communicating BHRT to Patients
Many patients arrive with strong preconceptions — either enthusiasm from wellness media or fear from outdated studies. Your role is to provide balanced, evidence-based counseling. Acknowledge their concerns, explain the distinctions between types of HRT, and frame decisions in terms of individual risk/benefit. Patients who feel heard and educated are far more likely to comply with monitoring and follow up consistently.
Documentation and Monitoring
When prescribing compounded hormones, document your clinical rationale, the specific formulation and dose, and why a compounded product was chosen over an FDA-approved alternative. Establish a monitoring schedule (symptom review and labs at 6–8 weeks post-initiation, then every 6 months). Thorough documentation protects you clinically and demonstrates the professional standard of care.